SAN FRANCISCO – Exuberance over China's ascendant biopharma sector formed a near-deafening roar at the 6th Annual Wuxi Global Forum Tuesday, where Ruyi He, chief scientist of the CFDA's Center for Drug Evaluation (CDE), spoke to the accelerating pace of the Republic's regulatory reform.